New drug duo aims to wipe out lingering cancer cells before transplant
NCT ID NCT07443488
Summary
This study is testing a combination of two drugs, olverembatinib and inotuzumab ozogamicin, in adults with a specific type of acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug combo can effectively clear any remaining cancer cells after initial treatment, helping patients get into a deeper remission faster. If successful, this could better prepare patients for a potentially curative stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.